-+ 0.00%
-+ 0.00%
-+ 0.00%
Orexo resubmits IZIPRY NDA to FDA for opioid overdose treatment
Share
Listen to the news
Orexo resubmits IZIPRY NDA to FDA for opioid overdose treatment
  • Orexo completed its FDA resubmission of the IZIPRY (naloxone nasal powder) NDA on Sept. 29, 2026.
  • Filing aims to address deficiencies cited in the FDA’s July 2024 complete response letter.
  • FDA acceptance decision and an updated review timeline are expected in the coming weeks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orexo AB published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending